Clinical Trials Browser

Phase 1/2 × Pluvicto × 1 year × Clear all

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Phase 1/2 Recruiting

123 enrolled

Genitourinary

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT05113537 2026-04-13

UPLIFT

Phase 1/2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT05682443 2025-12-02

PRESERVE-006

Phase 1/2 Active not recruiting

148 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06574880 2025-11-24

STARLiT

Phase 1/2 Recruiting

45 enrolled

Genitourinary

Prostatic Neoplasms

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1/2 Active not recruiting

50 enrolled 19 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

P300

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

UPLIFT

PRESERVE-006

STARLiT

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC